scholarly journals HFE gene knockout produces mouse model of hereditary hemochromatosis

1998 ◽  
Vol 95 (5) ◽  
pp. 2492-2497 ◽  
Author(s):  
X. Y. Zhou ◽  
S. Tomatsu ◽  
R. E. Fleming ◽  
S. Parkkila ◽  
A. Waheed ◽  
...  
2016 ◽  
Vol 8 (3) ◽  
pp. 241
Author(s):  
Damien Vitiello ◽  
Yvan Trzaskus ◽  
Rémi Thomasson ◽  
Haidar Djemai ◽  
Jean-François Toussaint ◽  
...  

2002 ◽  
Vol 122 (3) ◽  
pp. 789-795 ◽  
Author(s):  
Michael Steiner ◽  
Kenneth Ocran ◽  
Janine Genschel ◽  
Patrick Meier ◽  
Helga Gerl ◽  
...  

2013 ◽  
Vol 88 (4) ◽  
pp. 530-540 ◽  
Author(s):  
Fatima Mendonca Jorge Vieira ◽  
Maria Cristina Nakhle ◽  
Clarice Pires Abrantes-Lemos ◽  
Eduardo Luiz Rachid Cancado ◽  
Vitor Manoel Silva dos Reis

BACKGROUND: Porphyria cutanea tarda is the most common form of porphyria, characterized by the decreased activity of the uroporphyrinogen decarboxylase enzyme. Several reports associated HFE gene mutations of hereditary hemochromatosis with porphyria cutanea tarda worldwide, although up to date only one study has been conducted in Brazil. OBJECTIVES: Investigation of porphyria cutanea tarda association with C282Y and H63D mutations in the HFE gene. Identification of precipitating factors (hepatitis C, HIV, alcoholism and estrogen) and their link with HFE mutations. METHODS: An ambispective study of 60 patients with PCT was conducted during the period from 2003 to 2012. Serological tests for hepatitis C and HIV were performed and histories of alcohol abuse and estrogen intake were investigated. HFE mutations were identified with real-time PCR. RESULTS: Porphyria cutanea tarda predominated in males and alcohol abuse was the main precipitating factor. Estrogen intake was the sole precipitating factor present in 25% of female patients. Hepatitis C was present in 41.7%. All HIV-positive patients (15.3%) had a history of alcohol abuse. Allele frequency for HFE mutations, i.e., C282Y (p = 0.0001) and H63D (p = 0.0004), were significantly higher in porphyria cutanea tarda patients, compared to control group. HFE mutations had no association with the other precipitating factors. CONCLUSIONS: Alcohol abuse, hepatitis C and estrogen intake are prevalent precipitating factors in our porphyria cutanea tarda population; however, hemochromatosis in itself can also contribute to the outbreak of porphyria cutanea tarda, which makes the research for HFE mutations necessary in these patients


2021 ◽  
Vol 5 (2) ◽  
pp. 49
Author(s):  
AbdullaM Bashein ◽  
LailaMohamed Elghawi ◽  
KaltoomHassan Mahanna

Author(s):  
Martha-Spyridoula Katsarou ◽  
Maria Papasavva ◽  
Rozana Latsi ◽  
Nikolaos Drakoulis

2005 ◽  
Vol 84 (12) ◽  
pp. 802-806 ◽  
Author(s):  
Esmeralda Vizzi ◽  
Carmen Luisa Loureiro ◽  
Marlene Gerder ◽  
María de las Nieves Garcia-Casal ◽  
Alvaro Rodríguez-Larralde ◽  
...  

2001 ◽  
Vol 47 (7) ◽  
pp. 1147-1156 ◽  
Author(s):  
Elaine Lyon ◽  
Elizabeth L Frank

Abstract Background: Hereditary hemochromatosis is an inherited disorder of iron metabolism that is characterized by excessive iron deposition in major organs of the body. Chronic increased iron absorption leads to multiorgan dysfunction. Since the discovery of the gene responsible for the majority of cases, research has progressed rapidly to identify the gene product, the effects of mutations, and the implications for different populations. The protein product of the HFE gene is a transmembrane glycoprotein, termed HFE, that modulates iron uptake. Mutations in the HFE protein compromise its function and produce disease symptoms. Two mutations, C282Y and H63D, have been linked to the majority of disease cases. Approach: We reviewed the recent literature for the molecular basis of hereditary hemochromatosis. Genotypic information was combined with biochemical and clinical phenotypic information to achieve a better understanding of the disease mechanism. Content: This review provides a comprehensive discussion of known mutations in the HFE gene and their phenotypic expression. Diagnostic criteria using molecular genetic techniques in conjunction with traditional biochemical tests are provided. Current methods and limitations of molecular testing are examined in detail. A strategy for population screening and an algorithm for diagnosis that incorporates molecular testing are presented. Treatment by therapeutic phlebotomy and the use of blood obtained from hemochromatosis patients are discussed. Summary: Although the disease mechanism has not been completely elucidated, phenotypic and penetrance data are becoming available. Controversy still exists concerning the role of genetic testing in diagnosis and population screening.


Sign in / Sign up

Export Citation Format

Share Document